Showing results (751-760 of 771) with videos related to
Sort By:
Pageof 78
Bioorganic & Medicinal Chemistry Letters|March 29, 2018
Discovery of 4-ethoxy-7H-pyrrolo[2,3-d]pyrimidin-2-amines as potent, selective and orally bioavailable LRRK2 inhibitorsXiao Ding, Luigi Piero Stasi, Ming-Hsun Ho, et al.International Journal of Surgery (London, England)|December 27, 2024
Oral microbiota as a biomarker for predicting the risk of malignancy in indeterminate pulmonary nodules: a prospective multicenter studyQiong Ma, Chun-Xia Huang, Jia-Wei He, et al.Nature Biotechnology|December 11, 2024
Intestinal mucosal barrier repair and immune regulation with an AI-developed gut-restricted PHD inhibitorYanyun Fu, Xiao Ding, Man Zhang, et al.Bioorganic & Medicinal Chemistry Letters|December 8, 2018
5-Substituted-N-pyridazinylbenzamides as potent and selective LRRK2 inhibitors: Improved brain unbound fraction enables efficacyXiao Ding, Luigi Piero Stasi, Xuedong Dai, et al.RSC Medicinal Chemistry|December 15, 2025
Discovery and optimization of pyrrolopyrimidines as highly potent, selective and brain-penetrant LRRK2 inhibitorsJeffrey M Axten, Xiao Ding, Luigi Piero Stasi, et al.Frontiers in Aging Neuroscience|July 15, 2022
Identification of Therapeutic Targets for Amyotrophic Lateral Sclerosis Using PandaOmics - An AI-Enabled Biological Target Discovery PlatformFrank W Pun, Bonnie Hei Man Liu, Xi Long, et al.Oncogene|June 22, 2021
FOXM1 is required for small cell lung cancer tumorigenesis and associated with poor clinical prognosisSheng-Kai Liang, Chia-Chan Hsu, Hsiang-Lin Song, et al.Molecular Cancer|November 23, 2024
Single-cell RNA sequencing reveals immune microenvironment niche transitions during the invasive and metastatic processes of ground-glass nodules and part-solid nodules in lung adenocarcinomaYi-Feng Ren, Qiong Ma, Xiao Zeng, et al.Nature Communications|September 2, 2025
Optically-driven organic nano-step actuator for reconfigurable photonic circuitsJi-Zhe Zhang, Xin-Biao Xu, Yanjun Gong, et al.Bioorganic & Medicinal Chemistry Letters|August 5, 2017
Discovery of 5-substituent-N-arylbenzamide derivatives as potent, selective and orally bioavailable LRRK2 inhibitorsXiao Ding, Xuedong Dai, Kai Long, et al.Pageof 78